Genomic Vision announces the issue of the second tranche of bonds convertible into shares with warrants (OCABSA) for a net amount of 1.92 million euros, by decision of the Management Board on February 13.

This issue of two million OCABSA to Winance is accompanied by the issue of 525.000 bonds convertible into shares delivered in payment of the second quarter of the investor's commitment fee.

As a reminder, on April 11, 2022, the biotech company signed an agreement with Winance to set up a financing line through the issue of OCABSAs, for a total maximum net amount of 28.8 million euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.